Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Schedule of Revenue by Service Line (Details)

v3.23.3
Revenue Recognition - Schedule of Revenue by Service Line (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenue $ 5,762 $ 5,146 $ 17,145 $ 15,377
Biologics and drug delivery        
Disaggregation of Revenue [Line Items]        
Total revenue 3,487 2,246 9,531 6,808
Biologics and Drug Delivery - Disposable Products        
Disaggregation of Revenue [Line Items]        
Total revenue 455 798 1,395 2,873
Biologics and Drug Delivery - Services and license fees        
Disaggregation of Revenue [Line Items]        
Total revenue 3,032 1,448 8,136 3,935
Functional neurosurgery navigation and therapy        
Disaggregation of Revenue [Line Items]        
Total revenue 1,918 2,420 6,480 6,831
Functional Neurosurgery Navigation and Therapy - Disposable Products        
Disaggregation of Revenue [Line Items]        
Total revenue 1,874 2,045 5,550 5,706
Functional Neurosurgery Navigation and Therapy - Services        
Disaggregation of Revenue [Line Items]        
Total revenue 44 375 930 1,125
Capital equipment and software        
Disaggregation of Revenue [Line Items]        
Total revenue 357 480 1,134 1,738
Capital Equipment and Software - Systems and Software Products        
Disaggregation of Revenue [Line Items]        
Total revenue 81 287 432 1,171
Capital Equipment and Software - Services        
Disaggregation of Revenue [Line Items]        
Total revenue $ 276 $ 193 $ 702 $ 567